// App-Quantinova.ai

TPS630 : A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (? 25).

Researchers

Presenter

  • Maysa M. Abu-Khalaf

Principal Investigators

  • Sarah Schellhorn Mougalian

  • Tara Beth Sanft

  • Kert D. Sabbath

  • Michael DiGiovanna

  • William M. Sikov

  • Kerin B. Adelson

  • Andrea Silber

  • Debra S. Brandt

  • Kathleen E. Bober-Sorcinelli

  • Neal Fishbach

  • Wajih Zaheer Kidwai

  • Lajos Pusztai

  • Erin Wysong Hofstatter

  • Gina G. Chung

Medical Centers

  • Women & Infants Hospital, Providence, RI

  • Yale Shoreline Med Ctr, Madison, CTYale School of Medicine, New Haven, CTSmilow Cancer Ctr Torrington, Torrington, CT

  • Yale University School of Medicine, New Haven, CT

  • Yale School of Medicine, Bridgeport, CT

  • Yale Cancer Center, Yale School of Medicine, New Haven, CT

  • Smilow Cancer Hosp-Waterbury, Waterbury, CT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diabetes

  • Breast cancer

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Granulin precursor

  • Hemoglobin A1c

  • Human epidermal growth factor receptor 2

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Anastrozole

  • Everolimus

  • Exemestane

  • Letrozole

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02236572

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved